Revealed: How polyomavirus tricks our cells into helping it build its invasion route
(Michigan Medicine - University of Michigan) If every cell in our body is a factory, viruses are industrial spies who try to break in and take over. New findings about how one of the most mysterious types of spy - polyomaviruses -- accomplishes this feat could aid the fight against Merkel cell carcinoma, and diseases in organ transplant and cancer patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 24, 2017 Category: Cancer & Oncology Source Type: news
2 UAMS Cancer Researchers Get $1.6M
Two cancer researchers at the University of Arkansas for Medical Sciences have each received a four-year grant of $791,000 to support their work.
Aime Franco and Dr. Ling Gao have been awarded Research Scholar Grants from the American Cancer Society.
UAMS said the grants are among 109 national research and training grants totaling more than $45 million that will fund investigators at 75 institutions across the country. The grants go into effect July 1.
"Based on our extremely rigorous peer review system, we think these two young scientists represent some of the finest cancer researchers in the country," said Charles Saxe, ...
Source: Arkansas Business - Health Care - May 10, 2017 Category: American Health Source Type: news
Merck and Pfizer secure US FDA approval for Bavencio to treat skin cancer
Merck ’s biopharmaceutical business EMD Serono and Pfizer have obtained the US Food and Drug Administration’s (FDA) approval for a 20mg/mL Bavencio (avelumab) injection to treat patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggress… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 26, 2017 Category: Pharmaceuticals Source Type: news
Immunotherapy drug becomes first therapy approved by FDA for rare skin cancer
The U.S. Food and Drug Administration has granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 24, 2017 Category: Science Source Type: news
EMD Serono nabs FDA approval for rare skin cancer drug
The FDA has approved a drug for a rare form of skin cancer that was developed in part by researchers at an EMD Serono facility in Billerica.
The agency announced Thursday afternoon that it had approved avelumab, the first-ever treatment for metastatic Merkel cell carcinoma. The drug was jointly developed by German drugmaker Merck KGaA and Pfizer (NYSE: PFE), and will be sold by the companies as Bavencio. EMD Serono, based in Rockland, is the biopharma arm of Merck KGaA in the U.S. and Canada.
Bavencio… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 24, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news
FDA approves first treatment for rare form of skin cancer
The U.S. Food and Drug Administration has granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer. (Source: World Pharma News)
Source: World Pharma News - March 24, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Immunotherapy drug becomes first therapy approved by FDA for rare skin cancer
(Fred Hutchinson Cancer Research Center) The US Food and Drug Administration yesterday granted accelerated approval to the checkpoint inhibitor Bavencio (avelumab) for the treatment of patients with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. Avelumab is the first FDA-approved treatment for metastatic MCC and the first disease that the drug has ever been approved to treat. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 24, 2017 Category: Global & Universal Source Type: news
FDA Approves Drug for Rare Skin Cancer
(MedPage Today) -- Avelumab active in Merkel cell carcinoma (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 23, 2017 Category: American Health Source Type: news
Avelumab: First Drug Ever Approved for Merkel Cell Carcinoma Avelumab: First Drug Ever Approved for Merkel Cell Carcinoma
Patients who develop this rare but aggressive skin cancer have not had a specific therapy, until today ' s approval of a novel immunotherapy.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 23, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA approves first treatment for rare form of skin cancer
The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer. (Source: Food and Drug Administration)
Source: Food and Drug Administration - March 23, 2017 Category: American Health Source Type: news
Bavencio Approved for Rare Skin Cancer
THURSDAY, March 23, 2017 -- Bavencio (avelumab) has been approved by the U.S. Food and Drug Administration to treat a rare but aggressive form of skin cancer called Merkel cell carcinoma (MCC), the agency said Thursday in a news release.
The drug,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 23, 2017 Category: Journals (General) Source Type: news
Immune responses against a virus-related skin cancer suggest ways to improve immunotherapy
(Fred Hutchinson Cancer Research Center) Researchers at Seattle's Fred Hutchinson Cancer Research Center and the University of Washington say a new study suggests ways to improve immune therapy for certain cancers including a virus-associated form of Merkel cell carcinoma, a rare, aggressive skin cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 17, 2017 Category: Cancer & Oncology Source Type: news
Novel test enables earlier detection of Merkel cell carcinoma, Fred Hutch scientists say
(Fred Hutchinson Cancer Research Center) New research findings show how immune system marker can supplement and often outperform imaging studies for recurrence of Merkel cell carcinoma (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2016 Category: Cancer & Oncology Source Type: news
When hope returns: a new drug takes on a rare, aggressive skin cancer
Fred Ewart is taking a new immunotherapy drug in the hopes it will help him survive Merkel cell carcinoma. So far, it's working. (Source: CBC | Health)
Source: CBC | Health - June 19, 2016 Category: Consumer Health News Tags: News/Health Source Type: news
No Radiation Needed in Some Patients With Merkel Cell CarcinomaNo Radiation Needed in Some Patients With Merkel Cell Carcinoma
In certain patients with small Merkel cell carcinoma tumors, surgical excision without adjuvant radiation therapy (RT) of the primary site, may be appropriate, according to researchers. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2016 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
